Table 1 Baseline patient characteristics
Characteristics | Monotherapy (n = 79) | Combination therapy (n = 60) | P-value# |
|---|---|---|---|
Age, years | 71.4 ± 11.8 | 71.7 ± 12.1 | 0.89 |
Male sex, no. (%) | 55 (69.6) | 46 (76.7) | 0.36 |
Smokers, no. (%) | 43 (54.4) | 34 (56.7) | 0.79 |
Body mass index ± SD | 24.1 ± 3.1 | 23.7 ± 2.6 | 0.25 |
VAS score | 34.1 ± 11.1 | 32.3 ± 16.1 | 0.54 |
Percent predicted FEV1, %† | 58.0 ± 14.8 | 55.8 ± 16.1 | 0.42 |
Percent predicted FVC, %† | 71.3 ± 17.1 | 72.1 ± 18.2 | 0.47 |
Comorbidities, no. (%) | |||
Ischemic heart disease | 31 (39.2) | 27 (45.0) | 0.52 |
Heart failure | 20 (25.3) | 13 (21.7) | 0.63 |
Diabetes mellitus | 11 (13.9) | 10 (16.7) | 0.46 |
Lung cancer | 2 (2.5) | 6 (10.0) | 0.21 |
WBC | |||
1. > 10 × 109/L, no. (%) | 42 (53.1) | 34 (56.7) | 0.52 |
C-reactive protein (mg/L), median (IQR) | 46.0 (12–124) | 44.8 (18–113) | 0.73 |
PaO2 (mm Hg), median (IQRs) | 71.7 (41–99) | 72.8 (43–115) | 0.72 |
PaCO2 (mm Hg), median (IQRs) | 42.8 (27–90) | 40.9 (25–82) | 0.45 |
ICS, no. (%) | 76 (96.2) | 59 (98.3) | 0.08 |
SCS, course for current AECOPD, no. (%) | 30 (37.9) | 22 (36.7) | 0.34 |